Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 228-234

  Chen, Helen H W ^a   Yan, Jiang Jou ^a   Chen, Wen Chung ^a   Kuo, Macus Tien ^b   Lai, Yu Hsuan ^a   Lai, Wu Wei ^a   Liu, Hsiao Sheng ^a   Su, Wu Chou ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ATP7A; ATP7B; Cisplatin; Human copper transporter 1; Non small cell lung cancer; Prognosis

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; DOCETAXEL; GEMCITABINE; HUMAN COPPER TRANSPORTER 1; MENKES PROTEIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CORRELATION ANALYSIS; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TREATMENT RESPONSE;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CATION TRANSPORT PROTEINS; DRUG DISCOVERY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS;

EID: 84855418559     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.06.011     Document Type: Article

References (33)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Blinman P., Alam M., Duric V., McLachlan S.A., Stockler M.R. Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer 2010, 69:141-147.
3. Lustberg M.B., Edelman M.J. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 2007, 8:38-46.
4. NCCN Non-small cell lung cancer: NCCN clinical practice guidelines in oncology v.2 2010.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
6. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
7. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
8. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
9. Kuo M.T., Chen H.H., Song I.S., Savaraj N., Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007, 26:71-83.
10. Song I.S., Savaraj N., Siddik Z.H., Liu P., Wei Y., Wu C.J., et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004, 3:1543-1549.
11. Holzer A.K., Varki N.M., Le Q.T., Gibson M.A., Naredi P., Howell S.B. Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 2006, 54:1041-1049.
12. Song I.S., Chen H.H., Aiba I., Hossain A., Liang Z.D., Klomp L.W., et al. Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol 2008, 74:705-713.
13. Petris M.J., Smith K., Lee J., Thiele D.J. Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem 2003, 278:9639-9646.
14. Holzer A.K., Howell S.B. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006, 66:10944-10952.
15. Aida T., Takebayashi Y., Shimizu T., Okamura C., Higasimoto M., Kanzaki A., et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol 2005, 97:41-45.
16. Nakayama K., Kanzaki A., Terada K., Mutoh M., Ogawa K., Sugiyama T., et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 2004, 10:2804-2811.
17. Ishida S., McCormick F., Smith-McCune K., Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
19. Nakagawa T., Inoue Y., Kodama H., Yamazaki H., Kawai K., Suemizu H., et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep 2008, 20:265-270.
20. Hall M.D., Okabe M., Shen D.W., Liang X.J., Gottesman M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008, 48:495-535.
21. Miyashita H., Nitta Y., Mori S., Kanzaki A., Nakayama K., Terada K., et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncol 2003, 39:157-162.
22. Leonhardt K., Gebhardt R., Mossner J., Lutsenko S., Huster D. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. J Biol Chem 2009, 284:7793-7802.
23. Zisowsky J., Koegel S., Leyers S., Devarakonda K., Kassack M.U., Osmak M., et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007, 73:298-307.
24. Mangala L.S., Zuzel V., Schmandt R., Leshane E.S., Halder J.B., Armaiz-Pena G.N., et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009, 15:3770-3780.
25. Gupta A., Lutsenko S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med Chem 2009, 1:1125-1142.
26. Lutsenko S., Barnes N.L., Bartee M.Y., Dmitriev O.Y. Function and regulation of human copper-transporting ATPases. Physiol Rev 2007, 87:1011-1046.
27. Bertinato J., Swist E., Plouffe L.J., Brooks S.P., L'Abbe M.R. Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. Biochem J 2008, 409:731-740.
28. van den Berghe P.V., Folmer D.E., Malingre H.E., van Beurden E., Klomp A.E., van der Sluis B., et al. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem J 2007, 407:49-59.
29. Kim B.E., Nevitt T., Thiele D.J. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008, 4:176-185.
30. Blair B.G., Larson C.A., Safaei R., Howell S.B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res 2009, 15:4312-4321.
31. Chen H.H., Song I.S., Hossain A., Choi M.K., Yamane Y., Liang Z.D., et al. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol 2008, 74:697-704.
32. Chen H.H., Kuo M.T. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Metal-Based Drugs 2010, 1-7.
33. Ishikawa T., Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993, 268:20116-20125.